drug

bupropion SR

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by National Institute on Drug Abuse (NIDA)
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
NCT00307203Phase 4Completed

KOLs & investigators

1
A. Eden Evins, MD, MPHKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
National Institute on Drug Abuse (NIDA)
company
trial
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
PHASE4
trial
indication
Schizophrenia
indication
Tobacco-Use Disorder
indication
Smoking Cessation
indication
Schizophrenia
indication
KOL
A. Eden Evins, MD, MPH
KOL score 5
person